Bio-Techne SVP exercises options, settles taxes in stock
BIO-TECHNE Corp senior vice president and general counsel Shane Bohnen reported routine equity compensation activity.
Rhea-AI Filing Summary
BIO-TECHNE Corp senior vice president and general counsel Shane Bohnen reported routine equity compensation activity. On May 5, 2026, he exercised stock options to acquire 8,400 shares of common stock at an exercise price of $47.60 per share.
On the same date, 7,055 shares of common stock were disposed of at $56.68 per share to satisfy tax obligations, a tax-withholding disposition rather than an open-market sale. Following these transactions, Bohnen directly owned 7,249 shares of BIO-TECHNE common stock, and continued to hold a substantial package of unexercised options and restricted stock units that vest over several future dates.
Positive
- None.
Negative
- None.
Insider Trade Summary
8,400 shares exercised/converted
Exercise
17 txns
Insider
Bohnen Shane
Role
SVP - General Counsel
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 8,400 | $0.00 | $0.00 |
| Exercise | Common Stock | 8,400 | $47.60 | $400K |
| Exercise Price or Tax Liability | Common Stock | 7,055 | $56.68 | $400K |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Performance Stock Option (Right to Buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 67,975 contracts for 67,527 underlying shares (Direct);
Common Stock — 7,249 shares (Direct);
Restricted Stock Units — 10,383 contracts (Direct);
Performance Restricted Stock Units — 28,806 contracts (Direct);
Performance Stock Option (Right to Buy) — 12,924 contracts (Direct)
Footnotes (13)
- F1. Fully exercisable.
- F2. Options to purchase 876 shares vest on each of 8/15/2023, 8/15/2025 and 8/15/2026, and options to purchase 880 shares vest on 8/15/2024.
- F3. Options to purchase 982 shares vest on each of 4/3/2024, 4/3/2025, 4/3/2026 and 4/3/2027.
- F4. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F5. Options to purchase 4,076 shares vest on 8/15/2024 and 8/15/2026, and options to purchase 4,075 shares vest on 8/15/2025 and 8/15/2027.
- F6. 49 restricted stock units vest on 8/15/2026.
- F7. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F8. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F9. 1,669 restricted stock units vest on each of 8/15/2026 and 8/15/2027.
- F10. Options to purchase 3,372 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
- F11. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F12. 2,332 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
- F13. Options to purchase 5,966 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 5,965 shares vest on 8/15/2028.
Key Figures
Options exercised: 8,400 shares
Option exercise price: $47.60 per share
Tax-withholding shares: 7,055 shares
+5 more
8 metrics
Options exercised
8,400 shares
Common stock acquired via option exercise at $47.60 on May 5, 2026
Option exercise price
$47.60 per share
Exercise price for 8,400 stock options converted to common stock
Tax-withholding shares
7,055 shares
Common stock withheld to cover tax liabilities at $56.68 per share
Tax-withholding price
$56.68 per share
Price applied to 7,055 shares used for tax-withholding disposition
Shares owned after
14,304 shares
Total BIO-TECHNE common stock directly owned after transactions
Remaining options from exercised grant
448 options
Stock options at $47.60 remaining after 8,400-share exercise
Largest option position
17,897 underlying shares
Stock option with $53.60 exercise price expiring August 15, 2035
RSU holding
6,996 underlying shares
Restricted Stock Units representing BIO-TECHNE common stock
Key Terms
Restricted Stock Units, Performance Restricted Stock Units, Stock Option (Right to Buy), tax-withholding disposition, +1 more
5 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Performance Restricted Stock Units financial
"Vests in full or in part on 8/15/2026 if certain performance goals are achieved"
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) underlying Common Stock with specified exercise prices and expiration dates"
tax-withholding disposition financial
"Payment of exercise price or tax liability by delivering securities"
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
derivative exercise/conversion financial
"Exercise or conversion of derivative security"
FAQ
What insider transactions did BIO-TECHNE (TECH) report for Shane Bohnen?
BIO-TECHNE reported that SVP and general counsel Shane Bohnen exercised stock options for 8,400 common shares at $47.60 and had 7,055 shares withheld at $56.68 to cover tax obligations, reflecting routine equity compensation activity rather than an open-market trade.
Did the BIO-TECHNE (TECH) insider sale involve open-market selling?
The filing describes a tax-withholding disposition of 7,055 BIO-TECHNE shares at $56.68, not an open-market sale. These shares were withheld to satisfy tax liabilities related to an 8,400-share stock option exercise, a common administrative mechanism for employee equity awards.
What options did Shane Bohnen exercise in the latest BIO-TECHNE (TECH) filing?
Shane Bohnen exercised stock options covering 8,400 BIO-TECHNE common shares at a $47.60 exercise price. The Form 4 also shows that 448 options from this specific grant remain outstanding, alongside multiple other option and restricted stock unit awards with later expiration and vesting schedules.
Does Shane Bohnen still hold unexercised BIO-TECHNE (TECH) options and RSUs?
Yes. The derivative holdings table shows multiple unexercised stock option grants and restricted stock units tied to BIO-TECHNE common stock, including 17,897 underlying shares at a $53.60 exercise price plus additional RSU and performance RSU awards that vest on various future dates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
